HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

Merck unveils PD-1xVEGF bispecific data in NSCLC, remains tight-lipped on phase 3 plans

More than a year after licensing its PD-1xVEGF bispecific, Merck & Co. has finally unveiled the first clinical data from the antibody. The results suggest the drug boasts similar safety and efficacy in non-small cell lung cancer compared with the field’s frontrunners.

By FierceBiotech · Apr 17, 2026 · via FierceBiotech
Merck unveils PD-1xVEGF bispecific data in NSCLC, remains tight-lipped on phase 3 plans

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

Tags
pipelineformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
With Voxzogo under pressure, BioMarin touts trial win in label expansion bid
PipelineFiercePharma ↗
With Voxzogo under pressure, BioMarin touts trial win in label expansion bid
With phase 3 results that have “exceeded” BioMarin’s expectations, the California biotech looks set up to gain…
May 25, 2026
ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer
PipelineFiercePharma ↗
ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer
According to an abstract released ahead of the ASCO 2026 annual meeting, combining the TROP2-directed ADC with…
May 24, 2026
AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway
PipelineFiercePharma ↗
AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway
A three-way battle among TROP2 ADCs in first-line triple-negative breast cancer is forming as AstraZeneca and …
May 23, 2026